“Fusion and binding inhibition” key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches

References

• Ackerman AL, Cresswell P. (2004). Cellular mechanisms governing cross-presentation of exogenous antigens. Nat Immunol 5:678–84
   PubMed Web of Science ®Google Scholar
• Allaway GP, Davis-Bruno KL, Beaudry GA, et al. (1995). Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 11:533–9
   PubMed Web of Science ®Google Scholar
• Balzarini J, Van Laethem K, Peumans WJ, et al. (2006). Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 80:8411–21
   PubMed Web of Science ®Google Scholar
• Briz V, Poveda E, Soriano V. (2006). HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57:619–27
   PubMed Web of Science ®Google Scholar
• Buffa V, Stieh D, Mamhood N, et al. (2009). Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models. J Gen Virol 90:234–43
   PubMed Web of Science ®Google Scholar
• Cavrois M, Neidleman J, Yonemoto W, et al. (2004). HIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion. Virology 328:36–44
   PubMed Web of Science ®Google Scholar
• Chan DC, Chutkowski CT, Kim PS. (1998). Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci 95:15613–7
   PubMed Web of Science ®Google Scholar
• Chan DC, Fass D, Berger JM, Kim PS. (1997). Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263–73
   PubMed Web of Science ®Google Scholar
• Chang JJ, Altfeld M. (2009). TLR-mediated immune activation in HIV. Blood 113:269–70
   PubMed Web of Science ®Google Scholar
• Chauhan G, Rath G, Goyal AK. (2013). In-vitro anti-viral screening and cytotoxicity evaluation of copper–curcumin complex. Artif Cells Nanomed Biotechnol 41:276–81
   PubMed Web of Science ®Google Scholar
• Chen J, Lin A, Peng P, et al. (2015). Lipid composition has significant effect on targeted drug delivery properties of NGR-modified liposomes. Drug Deliv 23:1426–33
   PubMed Web of Science ®Google Scholar
• Córdoba EV, Arnáiz E, Francisco J, et al. (2013). Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro. AIDS 27:2053–8
   PubMed Web of Science ®Google Scholar
• Corsi F, Fiandra L, Rizzardini G. (2016). New perspectives on nanotechnology and antiretroviral drugs: a ‘small’ solution for a big promise in HIV treatment? AIDS 30:963–4
   PubMed Web of Science ®Google Scholar
• Das Neves J, Amiji MM, Bahia MF, Sarmento B. (2010a). Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 62:458–77
   PubMed Web of Science ®Google Scholar
• Das Neves J, Amiji MM, Bahia MF, Sarmento B. (2010b). Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv Drug Deliv Rev 62:458–77
   PubMed Web of Science ®Google Scholar
• Das Neves J, Nunes R, Rodrigues F, Sarmento B. (2016). Nanomedicine in the development of anti-HIV microbicides. Adv Drug Deliv Rev 103:57–75
   PubMed Web of Science ®Google Scholar
• Date AA, Destache CJ. (2013). A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials 34:6202–28
   PubMed Web of Science ®Google Scholar
• D'cruz OJ, Uckun FM. (2014). Vaginal microbicides and their delivery platforms. Expert Opin Drug Deliv 11:723–40
   PubMed Web of Science ®Google Scholar
• De Jaeghere F, Allemann E, Kubel F, et al. (2000). Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J Control Release 68:291–8
   PubMed Web of Science ®Google Scholar
• Delézay O, Yahi N, Fantini J. (1996). Detection of functional galactosylceramide (GalCer) receptors on CD4-negative HIV-1 target cells. Perspect Drug Discov Des 5:192–202
   Google Scholar
• Desai PP, Date AA, Patravale VB. (2012). Overcoming poor oral bioavailability using nanoparticle formulations – opportunities and limitations. Drug Discov Today: Technol 9:e87–95
   Google Scholar
• Dey B, Lerner DL, Lusso P, et al. (2000). Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol 74:4562–9
   PubMed Web of Science ®Google Scholar
• Di Gianvincenzo P, Marradi M, Martinez-Avila OM, et al. (2010). Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg Med Chem Lett 20:2718–21
   PubMed Web of Science ®Google Scholar
• Doms RW, Trono D. (2000). The plasma membrane as a combat zone in the HIV battlefield. Genes Dev 14:2677–88
   PubMed Web of Science ®Google Scholar
• Donzella GA, Schols D, Lin SW, et al. (1998). AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4:72–7
   PubMed Web of Science ®Google Scholar
• Eckert DM, Kim PS. (2001). Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci 98:11187–92
   PubMed Web of Science ®Google Scholar
• Eckert DM, Malashkevich VN, Hong LH, et al. (1999). Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell 99:103–15
   PubMed Web of Science ®Google Scholar
• Elechiguerra JL, Burt JL, Morones JR, et al. (2005). Interaction of silver nanoparticles with HIV-1. J Nanobiotechnol 3:1–10
   PubMedGoogle Scholar
• Elsabahy M, Wooley KL. (2012). Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41:2545–61
   PubMed Web of Science ®Google Scholar
• Emau P, Tian B, O’keefe B, et al. (2007). Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti‐HIV microbicide. J Med Primatol 36:244–53
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Pozniak AL, Johnson MA, et al. (2005). Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11:1170–2
   PubMed Web of Science ®Google Scholar
• Flomenberg N, Devine SM, Dipersio JF, et al. (2005). The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 106:1867–74
   PubMed Web of Science ®Google Scholar
• Fonteh PN, Keter FK, Meyer D. (2010). HIV therapeutic possibilities of gold compounds. Biometals 23:185–96
   PubMed Web of Science ®Google Scholar
• Franquelim HG, De-Sousa FF, Veiga AS, et al. (2011). Cationic liposomes are possible drug-delivery systems for HIV fusion inhibitor sifuvirtide. Soft Matter 7:11089–92
   Web of Science ®Google Scholar
• Fumakia M, Yang S, Gu J, Ho EA. (2016). Protein/peptide‐based entry/fusion inhibitors as anti‐HIV therapies: challenges and future direction. Rev Med Virol 26:4–20
   PubMed Web of Science ®Google Scholar
• Furuta RA, Wild CT, Weng Y, Weiss CD. (1998). Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Mol Biol 5:276–9
   Web of Science ®Google Scholar
• Galvin SR, Cohen MS. (2004). The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2:33–42
   PubMed Web of Science ®Google Scholar
• Gaurav C, Goutam R, Rohan KN, et al. (2014). (Copper–curcumin) β-cyclodextrin vaginal gel: delivering a novel metal–herbal approach for the development of topical contraception prophylaxis. Eur J Pharm Sci 65:183–91
   PubMed Web of Science ®Google Scholar
• Gaurav C, Goutam R, Rohan KN, et al. (2015a). In situ stabilized AgNPs and (Cu-Cur) CD dispersed gel, a topical contraceptive antiretroviral (ARV) microbicide. RSC Adv 5:83013–28
   Web of Science ®Google Scholar
• Gaurav C, Nikhil G, Deepti S, et al. (2015b). Albumin stabilized silver nanoparticles – clotrimazole β-cyclodextrin hybrid nanocomposite for enriched anti-fungal activity in normal and drug resistant Candida cells. RSC Adv 5:71190–202
   Web of Science ®Google Scholar
• Gaurav C, Saurav B, Goutam R, K Goyal A. (2015c). Nano-systems for advanced therapeutics and diagnosis of atherosclerosis. Curr Pharm Des 21:4498–508
   PubMed Web of Science ®Google Scholar
• Geijtenbeek TB, Kwon DS, Torensma R, et al. (2000). DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587–97
   PubMed Web of Science ®Google Scholar
• Goyal G, Garg T, Malik B, et al. (2015). Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv 22:1027–42
   PubMed Web of Science ®Google Scholar
• Greenberg ML, Cammack N. (2004). Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 54:333–40
   PubMed Web of Science ®Google Scholar
• Groot F, Welsch S, Sattentau QJ. (2008). Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 111:4660–3
   PubMed Web of Science ®Google Scholar
• Ham AS, Cost MR, Sassi AB, et al. (2009). Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res 26:502–11
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Hung RW, Lavasanifar A. (2011). Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 63:943–55
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ, Reiss P, et al. (2008). Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society – USA panel. JAMA 300:555–70
   PubMed Web of Science ®Google Scholar
• Henrich TJ, Kuritzkes DR. (2013). HIV-1 entry inhibitors: recent development and clinical use. Curr Opin Virol 3:51–7
   PubMed Web of Science ®Google Scholar
• Hladik F, Sakchalathorn P, Ballweber L, et al. (2007). Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26:257–70
   PubMed Web of Science ®Google Scholar
• Hu Q, Mahmood N, Shattock RJ. (2007). High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368:145–54
   PubMed Web of Science ®Google Scholar
• Ichiyama K, Yokoyama-Kumakura S, Tanaka Y, et al. (2003). A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 100:4185–90
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Lowy I, Fletcher CV, et al. (2000). Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 182:326–9
   PubMed Web of Science ®Google Scholar
• Kahle KM, Steger HK, Root MJ. (2009). Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding. PLoS Pathog 5:e1000674
   PubMed Web of Science ®Google Scholar
• Karim QA, Baxter C. (2013). Microbicides for the prevention of sexually transmitted HIV infection. Expert Rev Anti-Infect Ther 11:12–23
   Web of Science ®Google Scholar
• Kilgore NR, Salzwedel K, Reddick M, et al. (2003). Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope. J Virol 77:7669–72
   PubMed Web of Science ®Google Scholar
• Kish-Catalone T, Pal R, Parrish J, et al. (2007). Evaluation of-2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model. AIDS Res Hum Retrovirus 23:33–42
   PubMed Web of Science ®Google Scholar
• Koshiba T, Chan DC. (2003). The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 278:7573–9
   PubMed Web of Science ®Google Scholar
• Kuhmann SE, Platt EJ, Kozak SL, Kabat D. (2000). Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J Virol 74:7005–15
   PubMed Web of Science ®Google Scholar
• Kumar R, Kumar S, Jha SS, Jha AK. (2011). Vesicular system-carrier for drug delivery. Der Pharm Sin 4:192–202
   Google Scholar
• Kwong PD, Wyatt R, Robinson J, et al. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648–59
   PubMed Web of Science ®Google Scholar
• Labrosse B, Brelot A, Heveker N, et al. (1998). Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 72:6381–8
   PubMed Web of Science ®Google Scholar
• Lara HH, Ayala-Nuñez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. (2010). Mode of antiviral action of silver nanoparticles against HIV-1. J Nanobiotechnol 8:1
   PubMedGoogle Scholar
• Lara HH, Ixtepan-Turrent L, Treviño ENG, Singh DK. (2011). Use of silver nanoparticles increased inhibition of cell-associated HIV-1 infection by neutralizing antibodies developed against HIV-1 envelope proteins. J Nanobiotechnol 9:38
   PubMed Web of Science ®Google Scholar
• Lee B, Sharron M, Blanpain C, et al. (1999). Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 274:9617–26
   PubMed Web of Science ®Google Scholar
• Lekutis C, Olshevsky U, Furman C, et al. (1992). Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. JAIDS: J Acquir Immune Defic Syndr 5:78–81
   PubMed Web of Science ®Google Scholar
• Leroux JC, Cozens RM, Roesel JL, et al. (1996). pH-sensitive nanoparticles: an effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. Pharm Res 13:485–7
   PubMed Web of Science ®Google Scholar
• Li W, Yu F, Wang Q, et al. (2016). Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy. AIDS 30:827–38
   PubMed Web of Science ®Google Scholar
• Lin PF, Blair W, Wang T, et al. (2003). A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci 100:11013–18
   PubMed Web of Science ®Google Scholar
• Lindahl U. (2007). Heparan sulfate-protein interactions – a concept for drug design? Thromb Haemost-Stuttgart 98:109
   PubMed Web of Science ®Google Scholar
• Liu J, Bartesaghi A, Borgnia MJ, et al. (2008). Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109–13
   PubMed Web of Science ®Google Scholar
• Louis JM, Bewley CA, Clore GM. (2001). Design and properties of NCCG-gp41, a chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J Biol Chem 276:29485–9
   PubMed Web of Science ®Google Scholar
• Lu M, Blacklow SC, Kim PS. (1995). A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Mol Biol 2:1075–82
   Web of Science ®Google Scholar
• Maeda K, Nakata H, Koh Y, et al. (2004). Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 78:8654–62
   PubMed Web of Science ®Google Scholar
• Malavia NK, Zurakowski D, Schroeder A, et al. (2011). Liposomes for HIV prophylaxis. Biomaterials 32:8663–8
   PubMed Web of Science ®Google Scholar
• Mallipeddi R, Rohan LC. (2010a). Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv 7:37–48
   PubMed Web of Science ®Google Scholar
• Mallipeddi R, Rohan LC. (2010b). Progress in antiretroviral drug delivery using nanotechnology. Int J Nanomed 5:533
   PubMed Web of Science ®Google Scholar
• Marmor M, Hertzmark K, Thomas SM, et al. (2006). Resistance to HIV infection. J Urban Health 83:5–17
   PubMed Web of Science ®Google Scholar
• Matos PM, Castanho MA, Santos NC. (2010). HIV-1 fusion inhibitor peptides enfuvirtide and T-1249 interact with erythrocyte and lymphocyte membranes. PLoS One 5:e9830
   PubMed Web of Science ®Google Scholar
• Matthews T, Salgo M, Greenberg M, et al. (2004). Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 3:215–25
   PubMed Web of Science ®Google Scholar
• Mccarthy TD, Karellas P, Henderson SA, et al. (2005). Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol Pharm 2:312–18
   PubMed Web of Science ®Google Scholar
• Mcgowan I. (2014). The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv 11:69–82
   PubMed Web of Science ®Google Scholar
• Melikyan GB, Markosyan RM, Hemmati H, et al. (2000). Evidence that the transition of HIV-1 gp41 into a six-helix bundle, not the bundle configuration, induces membrane fusion. J Cell Biol 151:413–23
   PubMed Web of Science ®Google Scholar
• Montgomery CM. (2015). ‘HIV has a woman's face’: vaginal microbicides and a case of ambiguous failure. Anthropol Med 22:250–62
   PubMed Web of Science ®Google Scholar
• Müllertz A, Ogbonna A, Ren S, Rades T. (2010). New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol 62:1622–36
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakajima T, Koyanagi Y, et al. (1997). A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 186:1389–93
   PubMed Web of Science ®Google Scholar
• Nagashima KA, Thompson DA, Rosenfield SI, et al. (2001). Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 183:1121–5
   PubMed Web of Science ®Google Scholar
• Nandy B, Bindu DH, Dixit NM, Maiti PK. (2013). Simulations reveal that the HIV-1 gp120-CD4 complex dissociates via complex pathways and is a potential target of the polyamidoamine (PAMAM) dendrimer. J Chem Phys 139:024905
   PubMed Web of Science ®Google Scholar
• Narasimhan B, Goodman JT, Vela Ramirez JE. (2016). Rational design of targeted next-generation carriers for drug and vaccine delivery. Annu Rev Biomed Eng 18:25–49
   PubMed Web of Science ®Google Scholar
• Nikolic DS, Garcia E, Piguet V. (2007). Microbicides and other topical agents in the prevention of HIV and sexually transmitted infections. Expert Rev Anti-Infect Ther 5:77–88
   PubMed Web of Science ®Google Scholar
• Nishibu A, Ward BR, Jester JV, et al. (2006). Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli. J Invest Dermatol 126:787–96
   PubMed Web of Science ®Google Scholar
• Nittayananta W, Weinberg A, Malamud D, et al. (2016). Innate immunity in HIV‐1 infection: epithelial and non‐specific host factors of mucosal immunity – a workshop report. Oral Dis 22:171–80
   PubMed Web of Science ®Google Scholar
• Pardeike J, Hommoss A, Müller RH. (2009). Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 366:170–84
   PubMed Web of Science ®Google Scholar
• Patravale V, Kulkarni R. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56:827–40
   PubMed Web of Science ®Google Scholar
• Peek LJ, Middaugh CR, Berkland C. (2008). Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 60:915–28
   PubMed Web of Science ®Google Scholar
• Peng J, Wu Z, Qi X, et al. (2013). Dendrimers as potential therapeutic tools in HIV inhibition. Molecules 18:7912–29
   PubMed Web of Science ®Google Scholar
• Phogat S, Wyatt R, Karlsson Hedestam G. (2007). Inhibition of HIV‐1 entry by antibodies: potential viral and cellular targets. J Intern Med 262:26–43
   PubMed Web of Science ®Google Scholar
• Poxon S, Mitchell P, Liang E, Hughes J. (1996). Dendrimer delivery of oligonucleotides. Drug Deliv 3:255–61
   Google Scholar
• Qu J, Zhang L, Chen Z, et al. (2016). Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy? Drug Deliv 1–28
   PubMed Web of Science ®Google Scholar
• Raja A, Venturi M, Kwong P, Sodroski J. (2003). CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol 77:713–18
   PubMed Web of Science ®Google Scholar
• Rath G, Hussain T, Chauhan G, et al. (2015). Fabrication and characterization of cefazolin-loaded nanofibrous mats for the recovery of post-surgical wound. Artif Cells Nanomed Biotechnol 1–10
   PubMed Web of Science ®Google Scholar
• Rath G, Hussain T, Chauhan G, et al. (2016a). Collagen nanofiber containing silver nanoparticles for improved wound-healing applications. J Drug Target 24:520–9
   PubMed Web of Science ®Google Scholar
• Rath G, Hussain T, Chauhan G, et al. (2016b). Development and characterization of cefazolin loaded zinc oxide nanoparticles composite gelatin nanofiber mats for postoperative surgical wounds. Mater Sci Eng: C 58:242–53
   PubMed Web of Science ®Google Scholar
• Rimsky LT, Shugars DC, Matthews TJ. (1998). Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 72:986–93
   PubMed Web of Science ®Google Scholar
• Root MJ, Kay MS, Kim PS. (2001). Protein design of an HIV-1 entry inhibitor. Science 291:884–8
   PubMed Web of Science ®Google Scholar
• Root MJ, Steger HK. (2004). HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 10:1805–25
   PubMed Web of Science ®Google Scholar
• Rusnati M, Vicenzi E, Donalisio M, et al. (2009). Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol Ther 123:310–22
   PubMed Web of Science ®Google Scholar
• Sedwick C. (2012). How HIV sneaks aboard mature dendritic cells. PLoS Biol 10:e1001454
   PubMed Web of Science ®Google Scholar
• Sepulveda-Crespo D, Lorente R, Leal M, et al. (2014). Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine 10:609–18
   PubMed Web of Science ®Google Scholar
• Shenoy SR, O'keefe BR, Bolmstedt AJ, et al. (2001). Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther 297:704–10
   PubMed Web of Science ®Google Scholar
• Stantchev TS, Markovic I, Telford WG, et al. (2007). The tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages. Virus Res 123:178–89
   PubMed Web of Science ®Google Scholar
• Teissier E, Penin F, Pecheur EI. (2011). Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules 16:221–50
   Web of Science ®Google Scholar
• Tiberi M, Tintori C, Ceresola ER, et al. (2014). 2-aminothiazolones as anti-HIV agents which act as gp120-CD4 Inhibitors. Antimicrob Agents Chemother 58:3043–52
   PubMed Web of Science ®Google Scholar
• Tobiume M, Lineberger JE, Lundquist CA, et al. (2003). Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells. J Virol 77:10645–50
   PubMed Web of Science ®Google Scholar
• Van Lelyveld SF, Drylewicz J, Krikke M, et al. (2015). Maraviroc intensification of cART in patients with suboptimal immunological recovery: a 48-week, placebo-controlled randomized trial. PLoS One 10:e0132430
   PubMed Web of Science ®Google Scholar
• Veazey RS, Marx PA, Lackner AA. (2003). Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection. J Infect Dis 187:769–76
   PubMed Web of Science ®Google Scholar
• Vermeire K, Bell TW, Choi HJ, et al. (2003). The anti-HIV potency of cyclotriazadisulfonamide analogs is directly correlated with their ability to down-modulate the CD4 receptor. Mol Pharmacol 63:203–10
   PubMed Web of Science ®Google Scholar
• Vermeire K, Zhang Y, Princen K, et al. (2002). CADA inhibits human immunodeficiency virus and human herpesvirus 7 replication by down-modulation of the cellular CD4 receptor. Virology 302:342–53
   PubMed Web of Science ®Google Scholar
• Vijayakumar S, Ganesan S. (2012). Gold nanoparticles as an HIV entry inhibitor. Curr HIV Res 10:643–6
   PubMed Web of Science ®Google Scholar
• Vyas TK, Shah L, Amiji MM. (2006). Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites Expert Opin Drug Deliv 3:613–28
   Google Scholar
• Watson Buckheit K, Yang L, Buckheit RW, Jr. (2011). Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides. Antimicrob Agents Chemother 55:5243–54
   PubMed Web of Science ®Google Scholar
• Weissenhorn W, Dessen A, Calder LJ, et al. (1999). Structural basis for membrane fusion by enveloped viruses. Mol Membr Biol 16:3
   PubMed Web of Science ®Google Scholar
• Weissenhorn W, Dessen A, Harrison SC, et al. (1997). Atomic structure of the ectodomain from HIV-1 gp41. Nature 387:426–30
   PubMed Web of Science ®Google Scholar
• Wild CT, Shugars DC, Greenwell TK, et al. (1994). Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci 91:9770–4
   PubMed Web of Science ®Google Scholar
• Williamson MP, Mccormick TG, Nance CL, Shearer WT. (2006). Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J Allergy Clin Immunol 118:1369–74
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu J, Li X, Jasti B. (2007). Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv 14:381–7
   PubMed Web of Science ®Google Scholar